Personalized drug combos for advanced thyroid cancer
Official title: Network Pharmacology-based Personalized Drug Repurposing in Thyroid Carcinoma: a Pilot Feasibility Trial
Run by Radboud University Medical Center · NCT07485569 · Data updated 2026-11-12
This phase Ib study tests whether customized drug combinations, chosen from existing approved medicines based on a patient’s tumor genetics, can be safely given to people with advanced thyroid cancer when standard options are limited.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Radboud University Medical Center Academic / other |
| Locations | 1 site (Nijmegen) |
| Status | Recruiting |
| Started | October 1, 2026 |
| Main results expected | October 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT07485569 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with locally advanced or metastatic thyroid cancer (including ATC, PDTC, or RAI-refractory DTC) who have exhausted approved options and can undergo tumor biopsy for profiling.
✕Probably not a fit
Patients whose tumors do not show actionable targets or who cannot tolerate the chosen drug combinations may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an exploratory, single-arm phase Ib trial in patients with locally advanced or metastatic thyroid cancer who have no approved standard options. Participants undergo tumor profiling to identify personalized drug combinations, aiming to target multiple networks within the tumor. The study primarily assesses feasibility of administering these individualized regimens and safety, with secondary goals of monitoring tumor control. Each patient is treated for about four months, starting with tumor analysis to select a personalized treatment after consent. The approach uses network pharmacology to repurpose existing drugs and is conducted at Radboud University Medical Center with collaboration from Maastricht University and EU Horizon programs.
Why it matters
Potential benefit: If successful, patients may receive tailored therapy that could better control tumor growth with manageable safety.
How similar studies have gone: Previous work in precision oncology shows mixed results; this study explores a novel, network-based repurposing approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available. * Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0). * Measurable disease per RECIST 1.1 * ECOG performance status ≤ 2 * Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception. Exclusion Criteria: * Inability to provide informed consent * Inability to obtain a (new) biopsy for molecular profiling * Pregnancy or breastfeeding. * Other active malignancies requiring therapy. * Neutropenia (ANC \< 1.5 × 10⁹/L). * Severe uncontrolled medical conditions (renal, cardiac, liver, respiratory).
Where it's running
-
Radboudumc
Nijmegen, Netherlands Recruiting
Study contacts
- Principal investigator: Romana Netea-Maier — Radboud University Medical Center
- Study coordinator: R Netea-Maier, Prof. Dr.
- Email: romana.netea-maier@radboudumc.nl
- Phone: +31243614599
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Treatment for advanced thyroid cancers using sacituzumab govitEcan
This study is testing a new drug called sacituzumab govitEcan to see if it can help people with advanced thyroid cancers that don't respond to traditional treatments.
-
F-18 Tetrafluoroborate PET/CT to find recurrent or residual differentiated thyroid cancer
This test will see if F-18 Tetrafluoroborate PET/CT finds recurrent or residual differentiated thyroid cancer better than standard F-18 FDG PET/CT in adults who had surgery and radioactive iodine and now have rising thyroglobulin or anti-thyroglobulin.
-
Meaning-Centered Therapy for Latinos for adults with advanced cancer
This study tests whether Meaning-Centered Psychotherapy for Latinos (MCP-L) can reduce anxiety and depression and improve quality of life compared with CBT in Spanish-speaking adults with advanced cancer.
-
Sacituzumab tirumotecan with or without tislelizumab for advanced thyroid cancer
This trial tests sacituzumab tirumotecan, given alone or together with the immunotherapy tislelizumab, in adults with unresectable or metastatic anaplastic, poorly differentiated, or radioactive iodine‑refractory differentiated thyroid cancer to see if it slows disease or improves survival.
-
Combining XL092 and cemiplimab for BRAF V600E–wildtype anaplastic thyroid cancer
This trial will test whether giving XL092 plus cemiplimab before surgery is safe and doable for adults with BRAF V600E–wildtype anaplastic thyroid cancer.
-
Predicting challenges in thyroid surgery
This study is trying to find out which factors can help doctors predict how challenging thyroid surgery will be for patients with thyroid cancer so they can plan better and keep patients safe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.